Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
23 mai 2022 08h00 HE
|
Recce Pharmaceuticals
Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee approves cohort six dosing at 4,000mg;...
Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level
13 avr. 2022 08h00 HE
|
Recce Pharmaceuticals
Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee...
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
12 avr. 2022 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
30 mars 2022 08h00 HE
|
Recce Pharmaceuticals
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety Committee to review cohort four data – expect...
Recce Pharmaceuticals Receives Research and Development (R&D) Incentive Rebate
29 mars 2022 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, March 29, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
08 mars 2022 08h00 HE
|
Recce Pharmaceuticals
Highlights: Independent Safety Committee unanimously recommends cohort four (RECCE® 327 at 1,000mg) to commence; a 20-fold increase from cohort one dose (50mg)Cohort four subjects recruited - RECCE®...
Recce Pharmaceuticals Announces Final Subjects Dosed in Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
23 févr. 2022 08h00 HE
|
Recce Pharmaceuticals
Highlights: Final three subjects in cohort three have been intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well toleratedMilestone achieved with 10 total subjects dosed, maximizing...
Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
08 févr. 2022 08h00 HE
|
Recce Pharmaceuticals
Highlights: Seven subjects in cohort three intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well tolerated Minimum recruited subjects met (7); additional three (3) at this...
Recce Pharmaceuticals Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
19 janv. 2022 08h00 HE
|
Recce Pharmaceuticals
Highlights: Seven subjects in cohort two intravenously dosed with RECCE® 327 (R327) at 150mg met all endpoints - indicating R327 is safe and well toleratedIndependent Safety Committee clears third...
Recce Pharmaceuticals Announces Positive Safety Data from First Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
10 janv. 2022 08h00 HE
|
Recce Pharmaceuticals
Highlights: Nine subjects in cohort one intravenously dosed with RECCE® 327 at 50mg meets all endpoints, indicating to be safe and well toleratedIndependent Safety Committee clears second study...